C4 Therapeutics, Inc.
CCCC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $161 | $102 | $113 | $254 |
| - Cash | $59 | $78 | $51 | $55 |
| + Debt | $61 | $63 | $64 | $66 |
| Enterprise Value | $164 | $86 | $126 | $264 |
| Revenue | $11 | $6 | $7 | $5 |
| % Growth | 73.8% | -10.7% | 39.8% | – |
| Gross Profit | $11 | $6 | $7 | $3 |
| % Margin | 100% | 100% | 100% | 65.9% |
| EBITDA | -$32 | -$28 | -$29 | -$33 |
| % Margin | -282.3% | -431.5% | -396.6% | -631.2% |
| Net Income | -$32 | -$26 | -$26 | -$35 |
| % Margin | -286.4% | -402.6% | -363.7% | -667.8% |
| EPS Diluted | -0.44 | -0.37 | -0.37 | -0.49 |
| % Growth | -18.9% | 0% | 24.5% | – |
| Operating Cash Flow | -$31 | -$12 | -$33 | -$18 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$32 | -$12 | -$33 | -$18 |